WallStSmart

Edwards Lifesciences Corp (EW)vsNuwellis Inc (NUWE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 71784% more annual revenue ($6.30B vs $8.77M). EW leads profitability with a 17.4% profit margin vs -217.2%. NUWE trades at a lower P/E of 0.0x. EW earns a higher WallStSmart Score of 61/100 (C+).

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 6.0Quality: 6.0
Piotroski: 3/9Altman Z: 4.48

NUWE

Hold

37

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 5.5
Piotroski: 2/9Altman Z: -73.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+68.2%)

Margin of Safety

+68.2%

Fair Value

$249.70

Current Price

$85.76

$163.94 discount

UndervaluedFair: $249.70Overvalued

Intrinsic value data unavailable for NUWE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW3 strengths · Avg: 9.3/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

NUWE4 strengths · Avg: 9.5/10
P/E RatioValuation
0.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
26.2%8/10

Revenue surging 26.2% year-over-year

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
46.3x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

NUWE4 concerns · Avg: 2.5/10
Market CapQuality
$177,9503/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-657.5%2/10

ROE of -657.5% — below average capital efficiency

EPS GrowthGrowth
-99.2%2/10

Earnings declined 99.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Altman Z-Score, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : NUWE

The strongest argument for NUWE centers on P/E Ratio, Price/Book, Debt/Equity. Revenue growth of 26.2% demonstrates continued momentum.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.3x leaves little room for execution misses.

Bear Case : NUWE

The primary concerns for NUWE are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

EW carries more volatility with a beta of 0.85 — expect wider price swings.

NUWE is growing revenue faster at 26.2% — sustainability is the question.

NUWE generates stronger free cash flow (-3M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EW scores higher overall (61/100 vs 37/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Nuwellis Inc

HEALTHCARE · MEDICAL DEVICES · USA

Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.

Want to dig deeper into these stocks?